Download VMV CV PUBLIC resume 20161128

Victor M. Villalobos, M.D., Ph.D.
University of Colorado Anschutz Medical Campus
1665 Aurora Court
Anschutz Cancer Pavilion Room 5329, mail stop F704
Aurora, CO
PROFESSIONAL/ACADEMIC APPOINTMENTS
9/15/2014 – current
Assistant Professor of Medicine
Division of Medical Oncology
University of Colorado Anschutz Medical Campus
9/15/2014 – current
Director, Sarcoma Medical Oncology
University of Colorado Anschutz Medical Campus
5/1/2015 – current
Director, T3 (Target-based Therapeutics Team), a multi-disease
clinical research team dedicated to basket cohort, target based and
supportive oncology trials.
University of Colorado Anschutz Medical Campus
7/1/2013 – 9/3/2014
Instructor of Medicine
Sarcoma, unknown primary cancers, and rare tumors clinic.
Division of Medical Oncology
Stanford University Medical Center
TRAINING
7/1/2008 – 6/30/2010
Internal Medicine Residency
Stanford University Medical Center
7/1/2010 – 6/30/2013
Fellowship in Medical Oncology
Stanford University Medical Center
EDUCATION
1995 – 1999
Baylor University; Waco, TX
Bachelor of Science, Biochemistry, Emphasis on Organic Synthesis
Research Advisor: Kevin Pinney, Ph.D.
1999 – 2008
Washington University School of Medicine; St. Louis, MO
Doctor of Medicine, May 2008
Doctor of Philosophy in Chemical Biology, February 2007
Research Advisor: David Piwnica-Worms, M.D., Ph.D.
Thesis: “Development and Characterization of Novel Optical
Biosensors for Real-Time Interrogation of Signal Transduction
Cascades in Live Cells.”
2012
Stanford University; Stanford, CA
Intensive Course in Clinical Research: Study Design and
Performance
Stanford Center for Clinical and Translational Education and
Research
BOARD CERTIFICATION AND LICENSING
5/2008
8/16/2012
11/13/2013
8/2014
Physician and Surgeon License in California
Lic# CA-A109396
Board certification in Internal Medicine (ABIM)
Board certification in Medical Oncology (ABIM)
Physician License in Colorado
Lic # DR.0054330
PROFESSIONAL SOCIETIES
2001 – 2010
2010 – present
2012 – present
2012 – current
2013 – present
2014 – present
2015 – present
Society for Molecular Imaging
American Society of Clinical Oncology
American College of Physicians
Member Sarcoma Alliance through Research and Collaboration
(SARC)
Connective Tissue Oncology Society
SWOG
Rocky Mountain Oncology Society
PROFESSIONAL APPOINTMENTS & HONORS
2011 – 2014
2011 – 2014
2011 – 2014
2011 – 2014
2013
2012 – 2014
2014 – current
2014 – current
2014 – current
2014 – 2015
2015 – current
2015 – current
2015 – current
2016 – current
2016 – current
ASCO University Committee
ASCO Professional Development Committee
ASCO Oncology Training Programs Subcommittee
ASCO Integrated Media and Technology Committee
ASCO Excellence in Teaching Award Selection Committee
Planning Committee: Stanford Multidisciplinary Management of
Cancers
Associate Editor – ASCO University Editorial Board
Steering Committee Member – University of Colorado Denver
Molecular Tumor Board
Member, SWOG Early Therapeutics and Rare Cancers Committee
Member, SWOG Sarcoma Survivorship Subcommittee
NCCN Bone Cancer Guideline Panel Member
Member, Intermountain Cancer Center Molecular Tumor Board
Study Section and Grant Review - FDA Orphan Products
Development
Rocky Mountain Oncology Society Board Member
Study Section and Grant Review - FDA Orphan Products
Development - Orphan Products Natural History Grants program
JOURNAL PEER-REVIEWER
2014 – current
2016
2016
ASCO University Editorial Board
Journal of Oncology Practice
Scientific Reports
2016
2016
2016
Case Reports in Oncological Medicine
JCO Precision Medicine
Oncology Board Review Manual
HONORS AND AWARDS
2002 – 2003
2013 – 2015
2015 – 2017
Nuclear Medicine Training Grant, Department of Energy
NIH Loan Repayment Program Award 2013-2015
Hope Foundation – SWOG Rare Tumors Fellow
CLINICAL EXPERTISE
2014 – current
2008 – 2014
University of Colorado Hospital – Anschutz Medical Campus
- Director, Sarcoma Medical Oncology
Mentor: Anthony Elias, MD
- Early phase developmental therapeutics
Mentors: Gail Eckhardt, MD; Wells Messersmith, MD
Stanford University Hospitals and Clinics, Stanford, CA.
- Soft Tissue and Bone Sarcoma
Mentors: Kristen Ganjoo, MD; Sant Chawla, MD, FRACP
- Carcinoma of unknown primary, ovarian, and other rare cancers
- Early phase Developmental therapeutics
Mentors: Branimir Sikic, MD; Dmitri Colevas MD
CLINICAL AND TRANSLATIONAL SCIENCE RESEARCH
2016 – current
2016 – current
2015 – current
2015 – current
2015 – current
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded)
Study Evaluating Gemcitabine and Docetaxel With or Without
Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Role: Principal investigator
Sponsor: Eli Lilly
M15-394 A Multicenter, Phase I, Open-Label, Dose-Escalation Study
of ABBV-085, an Antibody Drug Conjugate, in Subjects with
Advanced Solid Tumors (COMIRB 16-0263) (PRMS 16-33)
Role: Principal investigator
Sponsor: Abbvie
Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in
Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory
Synovial Sarcoma
Role: Principal investigator
Sponsor: Epizyme
NCI - EAY131 - Molecular Analysis for Therapy Choice (MATCH)
Role: SWOG Study Co-Chair/Champion
Sponsor: ECOG-ACRIN
Medimmune – A Phase 1 Study of MEDI4736 (Anti-PD-L1
Antibody) in Combination with Tremelimumab (Anti-CTLA-4
Antibody) in Subjects with Advanced Solid Tumors who Have
Received, Progressed, or are Intolerant to Standard Therapy and
2015 – 2016
2015 – current
2015 – current
2015 – current
2015 – current
2014 – current
2014 – current
2014 – current
Have Received No More Than 3 Prior Therapies for Metastatic or
Recurrent Disease.
Role: Principal Investigator
Sponsor: Medimmune
A091401: Phase II Study of Nivolumab with or Without Ipilimumab
in Patients with Metastatic or Unresectable Sarcoma
Role: Principal Investigator
Sponsor: ALLIANCE
A091202 - A Phase II Randomized, Double Blinded Study Of The
Peroxisome Proliferator-Activated Receptor Gamma Agonist,
Efatutazone Vs. Placebo In Patients With Previously Treated,
Unresectable Myxoid Liposarcoma
Role: Principal Investigator
Sponsor: ALLIANCE
ARST1321 - Pazopanib Neoadjuvant Trial in NonRhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase
II/III Randomized Trial of Preoperative Chemoradiation or
Preoperative Radiation Plus or Minus Pazopanib
Role: Principal Investigator/SWOG Co-Chair/Champion
Sponsor: NRG
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in
Selected Advanced Solid Tumors
Role: Principal Investigator
Sponsor: Pharmamar
A Phase 3, Randomized (1:1), Double-Blind, Placebo-Controlled,
Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus
Placebo in Patients with Advanced or Metastatic Soft Tissue
Sarcoma (excluding Kaposi’s and GIST) which is not amenable to
treatment with surgery or radiotherapy with curative intent (may
have had any number of prior systemic cytotoxic therapies for
advanced/metastatic disease except prior treatment with
anthracyclines).
Role: Principal investigator
Sponsor: Eli Lilly
An Open-Label Study to Evaluate the Pharmacokinetics of
Doxorubicin following the Concomitant Intravenous Administration
of Olaratumab (IMC-3G3) to Patients with Advanced Soft Tissue
Sarcoma
Role: Principal Investigator
Sponsor: Eli Lilly and Co.
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety,
Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of
Orally Administered AG-120 in Subjects with Advanced Solid
Tumors, Including Glioma, with an IDH1 Mutation
(Chondrosarcoma)
Role: Co-Investigator
Sponsor: Agios Pharmaceuticals
A Multi-Center, Open Label, First In Human, Phase I Dose
Escalation Study To Investigate Safety, Tolerability,
Pharmacokinetics, And Pharmacodynamics Of RO6839921, An
MDM2 Antagonist Following Intravenous Administration In
2014 – current
2014 – current
2014 – current
2012 – 2014
2013 – 2014
2011 – 2012
2011- 2012
2011 – 2012
Patients With Advanced Malignancies, Including Acute Myeloid
Leukemia (AML)
Role: Co-Investigator
Sponsor: Roche
A Multicenter, Randomized, Open-Label Phase 3 Study to
Investigate the Efficacy and Safety of Aldoxorubicin Compared to
Investigator’s Choice in Subjects with Metastatic, Locally Advanced,
or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were
Refractory to Prior Non-Adjuvant Chemotherapy
Role: Co-Investigator
Sponsor: CytRx Corporation
A Multicenter, Open-Label Single-Arm Study of YONDELIS
(trabectedin) for Subjects With Locally Advanced or Metastatic Soft
Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who
Have Relapsed or Are Refractory to Standard of Care Treatment
Role: Co-Investigator
Sponsor: Janssen Research & Development, LLC
A Randomized, Open-label, Phase II, Multi-center Trial of
Gemcitabine (G) with Pazopanib (P) or Gemcitabine (G) with
Docetaxel (T) in Previously Treated Subjects with Advanced Soft
Tissue Sarcoma.
Role: Co-Investigator
Sponsor: Medical University of South Carolina/GlaxoSmithKline
A First-in-Human Phase I Dose Escalation Trial of the Humanized
Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Patients with
Advanced Solid Malignancies.
Role: Co-investigator; Protocol co-developer; Coauthor
Sponsor: Stanford University
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic
Study of CDX-1127 in Patients with Selected Refractory or Relapsed
Hematologic Malignancies or Solid Tumors
Role: Co-investigator
Sponsor: Celldex Therapeutics
NCT01460134
HGS1029-C1078: Phase 1 Dose Ranging Study in Patients with
Advanced Solid Malignancies.
Role: Co-investigator
Sponsor: Human Genome Sciences
NCT00708006
OMP-21M18: A Phase 1 Dose Escalation Study of OMP-21M18 in
Subjects with Solid Tumors.
Role: Co-investigator
Sponsor: Oncomed Pharmaceuticals
NCT00744562
XL-184: A Randomized Discontinuation Study of XL184 in Subjects
with Advanced Solid Tumors: Non-Randomized Extension.
Role: Co-investigator
Sponsor: Exelixis
NCT00940225
2011 - 2013
2011 – 2014
2010 - 2013
2011 – 2014
2012 – 2014
A Phase II Study of Pazopanib in Patients with Imatinib and
Sunitinib Refractory or Intolerant Gastrointestinal Stroma
Tumors (GIST)
Role: Co-investigator; Coauthor
Sponsor: Glaxo-Smith-Kline/Investigator initiated
NCT 01391611
A Phase II Pilot Study of Cyclophosphamide, Doxorubicin, and
Vincristine alternating with Irinotecan and Temozolomide in
Patients with Newly Diagnosed Metastatic Ewing's Sarcoma
Role: Co-investigator
Type of Study: Investigator initiated multi-institutional study
Sponsor: Amgen
NCT 01313884
A Multi-center Single Agent Phase II Study of the Efficacy of
Nilotinib in Patients with Relapsed or Metastatic Pigmented
Villonodular Synovitis/Tenosynovial Giant Cell Tumor/diffusetype Giant Cell Tumor
Role: Co-investigator
Type of Study: Multi-center Study
Sponsor: Dana Farber Cancer Institute
NCT 01207492
A Randomized Controlled Study of Yondelis (Trabectedin) or
Dacarbazine for the Treatment of Advanced Liposarcoma or
Leiomyosarcoma previously Treated with an Anthracycline and
Ifosfamide
Role: Co-investigator
Type of Study: Multi-center Study
Sponsor: Johnson & Johnson
NCT 01343277
A Randomized Phase 3, Multicenter, Open-Label Study
Comparing TH-302 in Combination with Doxorubicin vs.
Doxorubicin Alone in Subjects with Locally Advanced
Unresectable or Metastatic Soft Tissue Sarcoma
Role: Co-investigator
Type of Study: Multi-center Study
Sponsor: Threshold Pharmaceuticals
NCT 01440088
BASIC SCIENCE RESEARCH
2011 – 2013
Stanford University, Stanford, CA
Elucidation of predictive biomarkers in ovarian cancer using the
TCGA cancer database.
I performed a fundamental reannotation of the TCGA clinical
dataset in ovarian cancer. We worked closely with several
bioinformaticians to include the more robust chemotherapy data to
identify several novel predictive biomarkers for platinum
sensitivity.
Mentor: Branimir Sikic, M.D.
2001 – 2007
Washington University School of Medicine, St. Louis, MO
I developed novel BRET (bioluminescence resonance energy
transfer) systems for imaging protease activity in living cells using
new donor proteins.
Mentor: David Piwnica-Worms, M.D., Ph.D.
2003 – 2008
Washington University School of Medicine, St. Louis, MO.
Developed novel non-destructive multicolored protein-protein
interaction sensors for use in vitro and in vivo, with the ability to
monitor two discreet protein interactions simultaneously in the
same cells in real-time.
Mentor: David Piwnica-Worms, M.D., Ph.D.
1996 – 1999
Baylor University, Waco, TX.
Synthesized novel antitumor therapeutics for optimized
bioavailability and function. Among these were drugs based on
combretastatin A-4, a colchicine analogue, with primary
mechanism of tubulin binding and inhibition of tubulin
polymerization.
Mentor: Kevin Pinney, Ph.D.
PUBLICATIONS
1) Villalobos VM, Hoffner B, Elias AD. We CAN study ultrarare tumors effectively in
this day and age, it just takes a cooperative approach: The role of dasatinib in assorted
indolent sarcomas. Cancer. 2016 Oct 3. doi: 10.1002/cncr.30377.
2) Willis S, Villalobos VM, Gevaert O, Abramovitz M, Williams C, Sikic BI, LeylandJones B. Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis. PLoS
One. 2016 Feb 17;11(2):e0149183.
3) Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, Wagner
AJ, D’Adamo D, McMillan A, Demetri GD, and George S. A Multicenter Phase II Study
of Pazopanib in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST)
Following Failure of at Least Imatinib and Sunitinib. Ann Oncol 2014 25 (1): 236-240.
4) Gevaert O, Villalobos V, Sikic BI, Plevritis S. Identification of ovarian cancer driver
genes by using module network integration of multi-omics data. Interface Focus 2013
3(4): 201130013.
5) Henry E, Villalobos V, Million L, Jensen KC, West R, Ganjoo K, Lebensohn A, Ford
JM, Telli ML. Chest wall leiomyosarcoma after breast-conservative therapy for earlystage breast cancer in a young woman with li-fraumeni syndrome. J Natl Compr Canc
Netw. 2012 Aug 1;10(8):939-42.
6) Villalobos VM, Naik S, Bruinsma M, Dothager RS, Pan MH, Samrakandi M, Moss B,
Elhammali A, Piwnica-Worms D. Dual-color Click Beetle Luciferase heteroprotein
fragment complementation assays. Chem Biol. 2010 Sep 24;17(9): 1018-29.
7) Gammon ST*, Villalobos VM*, Roshal M, Samrakandi M, Piwnica-Worms D.
Rational design of novel red-shifted BRET pairs: Platforms for real-time single-chain
protease biosensors Biotechnol Prog. 2009 Mar-Apr;25(2):559-69. *Co-first authors
8) Villalobos VM, Naik, S, Piwnica-Worms, D. Detection of protein-protein
interactions in live cells and animals with split firefly luciferase protein fragment
complementation Methods Mol Biol. 2008; 439:339-52.
9) Villalobos VM, Naik, S, Piwnica-Worms, D. Current state of imaging protein-protein
interactions in vivo with genetically encoded reporters. Annu Rev Biomed Eng. 2007;
9:321-49
10) Bullok KE, Gammon ST, Violini S, Prantner AM, Villalobos VM, Sharma V, PiwnicaWorms D. Permeation peptide conjugates for in vivo molecular imaging applications.
Molecular Imaging. 2006; 5: 1-15.
11) Piwnica-Worms, David; Luker, Kathryn E.; Villalobos, Victor M. (2005) Molecular
imaging of protein-protein interactions in living animals. In: Schuster DP, Blackwell
TS (Eds.), Lung Biology in Health and Disease: Molecular Imaging of the Lungs, Boca
Raton, FL: Taylor & Francis Group, pp. 313-326.
12) Gammon ST, Villalobos VM, Prior JL, Sharma V, Piwnica-Worms D. Quantitative
analysis of permeation peptide complexes labeled with Technetium-99m: Chiral and
sequence-specific effects on net cell uptake. Bioconjugate Chemistry. 2003; 14: 36876.
13) Ferdani, Ricardo; Hu, Jiaxin; Leevy, W. Matthew; Pajewska, Jolanta; Pajewski, Robert;
Villalobos, Victor; Barbour, Leonard J.; Gokel, George W. Solid-state evidence for
alkali metal to arene Pi-complexation. Journal of Inclusion Phenomena and
Macrocyclic Chemistry. 2001, 41: 7-12.
14) Pinney, K. G.; Mejia, M. P.; Villalobos, V. M.; Rosenquist, B. E.; Pettit, G. R.;
Verdier-Pinard, P.; Hamel, E. Synthesis and biological evaluation of aryl azide
derivatives of combretastatin A-4 as molecular probes for tubulin. Bioorganic &
Medicinal Chemistry. 2000, 8, 2417-2425.
ORAL PRESENTATIONS (Bolded represents national or international presentations)
1) Desmoid tumor trial using a gamma secretase inhibitor PF-03084014:
Connective Tissue Oncology Society International Meeting, Lisbon,
Portugal: Nov 2016.
2) Emerging Therapeutic Targets in Sarcoma: Cancer Center Grand Rounds, CME
lecture, Grand Junction, CO: Oct 2016.
3) A Phase II Study of a selective JAK1 Inhibitor (INCB39110) in Subjects with
Advanced Sarcomas: SWOG Group Meeting, San Francisco, CA: May 2016.
4) Emerging Targets in Sarcoma: University of Colorado, Cancer Center Symposium,
Denver, CO: Mar 2016.
5) A Patient Focused Look at Advanced Soft Tissue Sarcoma - Emerging
Targets in Sarcoma: Connective Tissue Oncology Society Annual Meeting,
CME lecture: Nov 2015.
6) Jak1 Inhibitor Trial Concept for Pleomorphic and Fibrosarcomas: SWOG
Group Meeting, Chicago IL: October 2015.
7) EAY131 – NCI Match: Trial Overview: SWOG Group Meeting, Chicago IL:
October 2015.
8) Molecular Targets in Sarcoma: University of Colorado, Flint Animal Cancer Hospital,
Colorado State University Veterinary School, Fort Collins, CO: July 2015.
9) Molecular Targets in Sarcoma: University of Colorado, Developmental Therapeutics
and Molecular Oncology Symposium, Denver, CO: Mar 2015.
10) Sarcomas: Diagnosis and Management: University of Colorado Health, Cancer Center
Rounds Poudre Valley Hospital, Fort Collins, CO: Feb 2015.
11) Cytotoxic Chemotherapy: University of Colorado – Anschutz Medical Campus, Cancer
Educational Series, Denver, CO: December 2014.
12) Progress in Cancer Immunotherapy: Dana Farber Cancer Center, Cancer Seminar,
Boston, MA: May 2014.
13) Progress in Cancer Immunotherapy: University of Colorado - Anschutz Medical
Campus, Cancer Seminar, Denver, CO: May 2014.
14) Progress in Cancer Immunotherapy: University of New Mexico Cancer Center, Grand
Rounds, Albuquerque, NM: February 2014.
15) Cytotoxic Chemotherapy: Stanford University Cancer Center, Stanford Cancer
Education Seminar Series, Palo Alto, CA: June 2014.
16) Cytotoxic Chemotherapy: Stanford University Medical School, Medical school lecture,
Palo Alto, CA: April 2014.
17) Diagnosis and Treatment of Occult Primary Cancers: Stanford University Cancer
Center, Stanford Cancer Education Seminar Series, Palo Alto, CA: June 2014.
18) Targeted Therapies in Cancer: Stanford University Medical School, Medical school
lecture, Palo Alto, CA: April 2014.
19) Cytotoxic Chemotherapy Chemotherapy Administration and
Pharmacology: ASCO University Faculty Presenter, Online Learning
activity, CME approved: August 2013.
20) Cytotoxic Chemotherapy: Stanford University Cancer Center, Stanford Cancer
Education Seminar Series, Palo Alto, CA: June 2013.
21) Sarcoma Clinical Cases: Multidisciplinary Management of Cancers, Invited Speaker,
Palo Alto, CA, June 2013.
22) Update on Chemotherapy for Sarcomas: Musculoskeletal Tumor Society,
Annual Meeting, Invited Speaker, San Francisco, CA: June 2013.
23) Cytotoxic Chemotherapy: Stanford University Medical School, medical school lecture,
Palo Alto, CA: April 2013.
24) Targeted Therapies in Cancer: Stanford University Medical School, Medical school
lecture, Palo Alto, CA: April 2013.
25) Cytotoxic Chemotherapy: Stanford University Cancer Center, Stanford Cancer
Education Seminar Series, Palo Alto, CA: June 2012.
26) Cytotoxic Chemotherapy: Stanford University Medical School, medical school lecture,
Palo Alto, CA: May 2012.
27) Targeted Therapies in Cancer: Stanford University Medical School, Medical school
lecture, Palo Alto, CA: April 2012.
POSTER PRESENTATIONS
1) V.M. Villalobos, S. Naik, D. Piwnica-Worms. Novel luciferase complementation pairs
to study protein-protein interactions in vivo. Fourth Annual Meeting of the Society for
Molecular Imaging. 2005; Cologne, Germany.
2) V.M. Villalobos, S. Naik, D. Piwnica-Worms. Novel two-color luciferase
complementation systems for imaging protein-protein interactions in live cells and
animals. Fifth Annual Meeting of the Society for Molecular Imaging. 2006; Kona,
Hawaii
3) Willis S, Villalobos VM, Young B, Leyland-Jones B. Frequently Deleted Genes in
Ovarian Cancer as Indicators of Platinum Response. Annual Meeting of the American
Society of Clinical Oncology. 2013; Chicago, IL.
4) Villalobos VM, Wang Y, Willis S, Leyland-Jones B, Sikic BI. EIF4EBP1 exhibits a
prognostic “Goldilocks” effect on ovarian cancer: a single gene biomarker for overall
survival and platinum response. Annual Meeting of the American Society of Clinical
Oncology. 2013; Chicago, IL
5) Villalobos VM, Wang Y, Willis S, Leyland-Jones B, Sikic BI. EIF4EBP1 exhibits a
prognostic “Goldilocks” effect on ovarian cancer: a single gene biomarker for overall
survival and platinum response. Molecular Therapeutics of Cancer Research
Conference 2013; Boulder, CO
6) Ansell S, Northfelt D, Flinn I, Burris H, Dinner S, Villalobos V, Sikic B, Pilja L, Yellin
M, Keler T, Davis T. A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors Early Data
from Ongoing Dose-Escalation in Hematologic Malignancies. Society for
Immunotherapy of Cancer (SITC) Annual Meeting. 2013; National Harbor, MD
7) Infante JR, Burris HA, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI,
Taylor MH, Northfelt DW, Carson WE, Pilja L, Hawthorne TR, Davis TA, Yellin MJ,
Keler T, Bullock T. Immunologic activity of an activating anti-CD27 antibody (CDX1127) in patients (pts) with solid tumors. Annual Meeting of the American Society of
Clinical Oncology. 2014; Chicago, IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 3027)
8) Ansell SM, Northfelt DW, Flinn I, Burris HA, Dinner SN, Villalobos VM, Sikic BI,
Taylor MH, Pilja L, Hawthorne TR, Yellin MJ, Keler T, Davis TA. Phase I evaluation of
an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced
hematologic malignancies. Annual Meeting of the American Society of Clinical
Oncology. 2014; J Clin Oncol 32:5s, 2014 (suppl; abstr 3024)
9) Mariano Pulla, Josep Tabernero, Victor Moreno, Jose Manuel Trigo Perez, Rafael
Lopez, Rebecca Kristeleit, Ahmad Awada, Alexandra Leary, Jerome Alexandre, JeanPierre Delord, Stefano Ferrari, Armando Santoro, Emilio Bajetta, Vivek Subbiah,
Steven Weitman, Victor Villalobos, Eric Raymond, Anna Sundlov, Pilar Lardelli, Sant
P. Chawla. A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in
selected advanced solid tumors. ASCO Annual Meeting. 2015; Chicago, IL.
10) Victor Villalobos, Mark Agulnik, Seth M. Pollack, Daniel A. Rushing, Arun Singh, Brian
A. Van Tine, Chukwuemeka Okereke, Wee Teck Ng, Damien M. Cronier. A phase I
open-label study to evaluate the effect of olaratumab on the pharmacokinetics (PK) of
doxorubicin (Dox) in patients with advanced soft tissue sarcoma (STS). AACR Annual
Meeting. 2016; New Orleans, LA.
11) Sikic B, Villalobos V et al. A first-in-human, first-in-class phase I trial of the anti-CD47
antibody Hu5F9-G4 in patients with advanced cancers. ASCO Annual meeting. 2016;
Chicago, IL.
12) Padda SK, Shah S, Narayanan S, Colevas AD, Fisher GA, Supan D, Wakelee HA, Aoki
R, Pegram MD, Villalobos VM, Liu J, Takimoto C, Chao M, Volkmer JP, Majeti R,
Weissman IL, Sikic BI. A first-in-human, first-in-class phase I trial of the anti-CD47
antibody Hu5F9-G4 in patients with advanced cancer. The 9th Annual Molecular
Therapeutics of Cancer Research Conference, Seattle, WA, Jul 2016.
13) Victor M. Villalobos, Stacey DaCosta, Sameer Ghate, Oluwakayode Adejoro, Jose
Perez. Compliance and persistence of pazopanib in metastatic soft tissue sarcoma
patients in the United States. CTOS Annual Meeting, 2016; Lisbon, Portugal.
14) William Tap, Victor M. Villalobos, Gregory M. Cote, Howard Burris, Filip Janku,
Olivier Mir, Murali Beeram, Andrew Wagner, Julia Auer, Hua Liu, Bin Wu, Katharine
Yen, Sam Agresta, Shuchi S. Pandya, Jonathan Trent. A phase 1 study of AG-120, an
IDH1 mutant enzyme inhibitor: results from the chondrosarcoma dose escalation and
expansion cohorts. CTOS Annual Meeting, 2016; Lisbon, Portugal.
15) Anne Rentz, Anne Skalicky, Sameer Ghate, Sant P. Chawla, Anthony P. Conley, Victor
M. Villalobos, Jose Perez. A new symptom-specific patient-reported outcome measure
for patients with soft tissue sarcoma. CTOS Annual Meeting, 2016; Lisbon, Portugal.
16) Victor M. Villalobos, Stacey DaCosta, Sameer Ghate, Oluwakayode Adejoro, Jose
Perez. Real-world treatment patterns of patients with metastatic soft tissue sarcoma in
the United States. CTOS Annual Meeting, 2016; Lisbon, Portugal.
UNDERGRADUATE AND GRADUATE LEADERSHIP ACTIVITIES
2003 – 2005
2004 – 2005
2003 – 2006
2004 – 2005
2005 – 2006
2005 – 2006
2006
1998 – 1999
1997 – 1998
1996 – 1999
Revised: Nov 2016
Senator in Graduate Student Senate, Washington University in St.
Louis
Co-chair Student Advisory Committee Washington University
Division of Biologic and Biomedical Sciences
Member Student Advisory Committee
Chair of Faculty Mentor Awards Committee
Committee for Diversity Programs
Committee for Medical Student Training Program
Committee for Institutional Accreditation
President Baylor University Golden Wave Band (Trombone)
Vice-President Baylor University Golden Wave Band
Member of Kappa Kappa Psi, Music service fraternity